Assessment of the effect of injection magnesium sulphate on fetal heart rate pattern in patients of eclampsia and preeclampsia

Reeta Singh*, Nirupama Rai, Neela Rai Sharma, Renu Mohan, Reena Srivastava, Harish Chand Tiwari

Department of Obstetrics and Gynaecology, B.R.D. Medical College, Gorakhpur, Uttar Pradesh, India

Received: 29 September 2016
Accepted: 05 October 2016

*Correspondence:
Dr. Reeta Singh,
E-mail: reetasinghhdr81@gmail.com

ABSTRACT

Background: To assess the effect of injection magnesium sulphate on fetal heart rate pattern in severe preeclampsia and eclampsia.

Methods: This is a hospital-based prospective observational study. It was conducted in the Dept. of Obstetrics and Gynaecology, BRD Medical College, Gorakhpur over period of one year from August 2014 to July 2015. Total 122 patients with diagnosis of severe preeclampsia and eclampsia who received injection MgSO4 were included in the study. Patients who delivered within 1 to 2 hrs of injection MgSO4, had pulmonary edema, respiratory depression, renal insufficiency, patients with recurrent convulsions not controlled by MgSO4 alone, fetus who had abnormal fetal heart rate pattern prior to administration of injection MgSO4, IUD baby, baby of gestational age <28 weeks were excluded from the study. Fetal heart rate pattern tracings were taken by CTG machine before administration of injection magnesium sulphate. Injection magnesium sulphate was given according to Pritchard Regime. Fetal heart rate pattern after injection MgSO4 were compared with fetal heart rate pattern before injection magnesium sulphate regarding all four parameters fetal heart rate, variability, accelerations and deceleration.

Results: Before injection magnesium sulphate mean fetal heart rate was 148.7 bpm±10.78. After 15 minutes mean fetal heart rate was 147.8 bpm±10.32. After 1 hour, 2 hour and 4 hour of injection magnesium sulphate mean fetal heart rate was 139.1 bpm±9.6, 139.2 bpm±9.8 and 137 bpm±9.4 respectively which was statistically significant (p value <0.001). Only patients with good variability were included in the study. After 1 hour of injection magnesium sulphate 16.4%, after 2 hour 23% and after 4 hour 31.1% developed poor variability i.e. <5. Before injection magnesium sulphate only 4% had no acceleration, after 15 minutes, 1 hour, 2 hour and 4 hour of injection magnesium sulphate 4.9%, 29.5%, 49% and 55% patients had no acceleration respectively. Before injection magnesium sulphate no patient had late deceleration. After 15 min only 2 patients had variable prolonged deceleration. After 1 hour, 2 hour and 4 hour 0%, 4.1% and 6.6% had late deceleration respectively.

Conclusions: Maternal exposure to magnesium sulphate in severe preeclampsia and eclampsia is associated with persistent fall in baseline fetal heart rate by approximately 9-11 bpm which appeared at 1 hr of injection MgSO4 but it is within the accepted normal range (110 bpm - 160bpm). Statistically significant patients developed decreased beat to beat variability <5 after 1 hr of injection MgSO4. Statistically significant patients developed absent acceleration. Few patients developed late decelerations but it was not significant.

Keywords: MgSO4 - Magnesium Sulphate, CTG - Cardiotocography
INTRODUCTION

Hypertensive disorders are among the commonest medical disorders during pregnancy and continue to be a major cause of maternal and perinatal morbidity and mortality. In developing countries they rank second only to anaemia with approximately 5-10% of all pregnancies complicated by some form of hypertensive disorder. In India incidence of preeclampsia as recorded from hospital statistics vary widely from 5-15%. Preeclampsia is a multisystem, highly variable disorder, unique to pregnancy characterized by hypertension and proteinuria. If left untreated, it can develop into eclampsia, the life-threatening occurrence of seizures during pregnancy.

Injection magnesium sulphate is given for prevention and treatment of convulsion in severe preeclampsia and eclampsia respectively. Dosage for severe preeclampsia is the same as for eclampsia. An effect of MgSO4 on FHR patterns is plausible because magnesium ions cross the fetal-placental membranes and fetal serum Mg++ levels rapidly equilibrate with maternal levels. Magnesium is a peripheral vasodilator and is assumed to cross the fetal blood-brain barrier, as it does in the mother. The FHR could potentially be affected through peripheral and central mechanisms. The effect of magnesium sulphate on fetal heart rate in case of severe preeclampsia and eclampsia has been studied. The effect of MgSO4 on fetal heart rate is observed by electronic fetal monitoring. Cardiotocography (CTG) is a special test for evaluation of fetal status. The basic objectives of CTG is to assess co-ordination between fetal central nervous system and the cardiovascular system based on the fact that a well-oxygenated healthy fetus with functionally intact CNS-cardiac axis will show accelerations(rise of FHR 15 beats/min for 15 seconds above baseline) with fetal movement the so called reactive CTG. In addition, good FHR variability (>5) suggest normal balance of sympathetic-parasympathetic activity, an indirect evidence of adequate oxygenation of fetal regulatory centers; indeed a normal FHR variability is the hallmark of fetal well-being.

Accepted normal parameters are:

1. Baseline FHR 110-160 beats/min.
2. Normal beat to beat variability should be 6-25 beats/min.
3. Presence of two or more accelerations of FHR exceeding 15 beats/min above the baseline and sustained for at least 15 seconds in a 20-min period. This pattern is termed as reactive.

CTG is used to detect fetal compromise related to fetoplacental pathology, cord compression, or other processes that may result in altered fetal cardiovascular function, such as fetal immaturity or maternal administration of central nervous system-depressant drugs.

METHODS

Study was done in the labour room of Obs and Gynae Department of BRD Medical College, Gorakhpur in eastern UP between time periods of August 2014 to July 2015. Patients with severe pre-eclampsia and eclampsia who received injection magnesium sulphate were included in study. Patients who delivered within 1 to 2 hrs of injection MgSO4, had pulmonary edema, respiratory depression, renal insufficiency, patients with recurrent convulsions not controlled by magnesium sulphate alone, fetus who had abnormal fetal heart rate pattern prior to administration, IUD baby, baby of gestational age <28 weeks were excluded from study. A written consent was taken after enrolling the patients. A detailed patient history, general systemic and obstetrical examination was done. Injection MgSO4 was given in severe preeclampsia and eclampsia. Fetal heart rate pattern tracings were taken by CTG machine before administration of injection magnesium sulphate. Injection magnesium sulphate was given according to Pritchard Regime. The loading bolus dose of 4 gram of Magnesium Sulphate is given slowly intravenously as a 20% solution at a rate not to exceed 1gm/min. It is followed promptly with 10 gram of 50% MgSO4 deep intramuscularly (5 gram in each buttock). Subsequently, 5 gram is given 4 hourly deep intramuscularly into alternate buttock. MgSO4 continued after 24 hours of last convulsion or delivery whichever is later. Fetal heart rate pattern tracings were taken after 15 minutes, 1 hour, 2 hour and 4 hour of injection magnesium sulphate. These tracings, after injection magnesium sulphate were compared with tracing before injection magnesium sulphate regarding all four parameters rate, variability, accelerations and decelerations.

RESULTS

Total 122 patients of severe preeclampsia and eclampsia were studied. Women were between the age group of 18-34 years. The maximum number of women were b/w 18-25 years. Maximum number of women had education up to secondary level i.e. 63.1% and 18.9% were illiterate. Maximum patients were primipara i.e. 68% followed by G2P3 18.9%, G2P2 8.9% and G1P5 5%. Maximum patients 90.2% were unbooked, rest 9.8% were booked. Approximately 70% patients had pregnancy between 30-34 weeks, rest 30% were above 34 weeks.

Table 1: Effect on mean fetal heart rate.

<table>
<thead>
<tr>
<th>Injection magnesium sulphate</th>
<th>Mean FHR</th>
<th>standard deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before injection magnesium sulphate</td>
<td>148.70</td>
<td>10.78</td>
</tr>
<tr>
<td>After 15 minute</td>
<td>147.8</td>
<td>10.32</td>
</tr>
<tr>
<td>After 1 hours</td>
<td>139.1</td>
<td>9.6</td>
</tr>
<tr>
<td>After 2 hours</td>
<td>139.2</td>
<td>9.8</td>
</tr>
<tr>
<td>After 4 hours</td>
<td>137.0</td>
<td>9.4</td>
</tr>
</tbody>
</table>

P value <0.001
Table 1 shows that before injection magnesium sulphate mean fetal heart rate was 148.7 bpm±10.78. After 15 minutes mean fetal heart rate was 148.7 bpm±10.32. After 1 hour, 2 hour and 4 hour of injection magnesium sulphate mean fetal heart rate was 139.1 bpm±9.6, 139.2 bpm±9.8 and 137 bpm±9.4 respectively.

Table 2 shows that all patients had good variability i.e. >5 before injection MgSO₄. After 1 hour of injection magnesium sulphate 16.4%, after 2 hour 23% and after 4 hour 31.1 % developed poor variability i.e. <5 which was in statistically significant patients (p value <0.001).

Table 3 shows, before injection magnesium sulphate only 4% had no acceleration, after 15 minutes, 1 hour, 2 hour and 4 hour of injection magnesium sulphate 4.9%, 29.5%, 49% and 55% patients had no acceleration respectively which was statistically significant (p value <0.001).

Table 4 shows, before injection magnesium sulphate no patient had late deceleration. After 2 hour out of 122, 5 (4.1%) had late deceleration. After 4 hour out of 122, 8 (6.6%) had late deceleration.

**DISCUSSION**

We observed that persistent drop in fetal heart rate was 9-11 bpm which appeared at 1 hour of bolus injection. In context to my study, studies of Stewart et al, Twickler et al, Kamitomo et al showed drop in fetal heart rate after injection magnesium sulphate. Stewart et al found fall in FHR mean from 139.9 bpm to 137.5 bpm after injection MgSO₄, Twickler et al and Kamitomo et al reported drop of 8-10 bpm and 14-15 bpm in basal FHR respectively. In present study drop of 9-11 bpm was found (P= <0.05).

We saw that after 1 hour of injection magnesium sulphate 16.4%,after 2 hour 23% and after 4 hour 31.1 % developed poor variability i.e. <5 which was statistically
significant (p value <0.001). Studies of Wright et al showed 8.3% patients developed decreased variability after 4 hour of injection magnesium sulphate.7 Lin et al, reported decreased variability in 40% cases after injection MgSO₄.8 Duffy et al found increased risk of absent or minimal variability and Hallak et al, found lower variability at 3 hour in MgSO₄ group compared to control group.9,10 Stewart et al, found minimal or absent variability during bolus infusion but corrected during steady state.4

We observed absence of acceleration in statically significant women after 1 hr of MgSO₄ bolus injection. Peaceman et al, reported 50% non- reactive NST tracing after injection MgSO₄.11 Guzman et al, reported reduced reactivity (accelerations of 15 bpm over 20 minutes).12 Stewart et al, Hallak et al, reported no significant difference in number of acceleration.4,10

It is observed in our study that late deceleration appeared in only few patients which was not in significant number. Stewart et al, Hallak et al, found no significant difference in deceleration.4,10 Duffy et al reported few prolonged decelerations.9

All 122 patients were discharged under satisfactory condition. 87.7% neonates were healthy and bedside, 12.3% required NICU admission. 4.1% neonates were admitted in NICU and expired.

CONCLUSION

Maternal exposure to magnesium in severe preeclampsia and eclampsia is associated with persistent decrease in basal fetal heart rate by approximately 9-11 bpm but it is within the accepted normal range (110 bpm-160bpm). Statistically significant patients developed decreased beat to beat variability <5 after 1 hr of injection MgSO₄. Statistically significant patients developed absence of acceleration .Few patients developed late decelerations but it was not significant. Stewart et al, Hallak et al, found no significant difference in deceleration. Duffy et al, reported few prolonged decelerations.

So Magnesium Sulphate is the best anticonvulsant drug for eclampsia and prevention of convulsion in severe preeclampsia having minimal or no effect on maternal and fetal outcome.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES
